Lipid Composition Modulates Organ-Specific Reactogenicity of Lipid Nanoparticles After Two Administrations
Authors:
- Mikhail BespalovMikhail Bespalov
- Lilia ShirokovaLilia Shirokova
- Elena MazuninaElena Mazunina
- Sofia KozlovaSofia Kozlova
- Evgeniia BykoniaEvgeniia Bykonia
- Olga VasilevaOlga Vasileva
- Sophia KonovalovaSophia Konovalova
- Yulia VenediktovaYulia Venediktova
- Maria VorontsovaMaria Vorontsova
- Vladimir GushchinVladimir Gushchin
- Denis LogunovDenis Logunov
- Roman IvanovRoman Ivanov
Open Access
- 28 October 2026
- journal article
- research article
- Published by MDPI AG in Pathophysiology
- Vol. 33 (4) , 81
Abstract
Background: Lipid nanoparticles (LNPs) can activate innate immunity, but the factors shaping repeat-dose reactogenicity remain unclear. We compared systemic, local, and organ-specific reactions after intramuscular administrations of empty LNPs containing ionizable lipids used in mRNA vaccines. Methods: Female BALB/c mice received two intramuscular injections, 2 weeks apart, of LNP-4 (four components, ALC-0315 as the sole ionizable lipid; 59 nm) or LNP-5 (five components, equimolar ALC-0315/SM-102 at the same total ionizable lipid content; 86 nm). Body weight was monitored for 15 days. Blood biochemical parameters, injection-site histology, and morphological and molecular markers in the hypothalamus, liver, lungs, and spleen were assessed 24 h after the second injection by histology, immunohistochemistry (IHC), immunofluorescence (IF), Western blotting, and quantitative PCR (qPCR). Results: Both LNPs were followed by transient body-weight loss, moderate biochemical changes, and local reactogenicity. The strongest organ-specific responses occurred in the liver and hypothalamus. Both LNPs induced hepatic sinusoidal dilation and leukocyte infiltration, but LNP-4 was associated with more myeloid cell numbers and higher inflammatory marker expression. In the hypothalamus, LNP-4 produced broader changes in inflammatory and myeloid marker expression than LNP-5. No marked structural damage was observed in the examined organs. Conclusions: Repeated LNP administration was followed by systemic and local reactogenicity, and organ-specific changes differed between the formulations, possibly reflecting lipid composition, particle size, and lipid dose. Carrier composition should be considered in the design and safety evaluation of LNP-based vaccine delivery systems.Keywords
Funding Information
- “Sirius” Federal Territory “Scientific and technological development of the “Sirius” Federal Territory” (3–03)
This publication has 64 references indexed in Scilit:
- Defining Composition–Cytokine Relationships Enables the Design of Lipid Nanoparticles with Programmed ImmunogenicitySmall, 2026
- Dual Ionizable Lipids (ALC0315 and SM102) in a Novel Lipid Nanoparticle Formulation Enhance In Vivo Delivery and Time‐Dependent Expression of Messenger RNA and Self‐Amplifying RNAChemMedChem, 2026
- Surface Charge‐Determined Protein Coronas of Nanoparticles Control Endothelial Cells Uptake Under Low Magnitude Shear StressExploration, 2026
- Redefining the timeline: a three-phase framework of hypothalamic microinflammation in metabolic diseaseReviews in Endocrine and Metabolic Disorders, 2025
- Miconazole attenuates LPS-induced lung inflammation by modulating alveolar macrophage polarization via promoting lipid metabolic reprogrammingInflammation Research, 2025
- Novel Less Toxic, Lymphoid Tissue‐Targeted Lipid Nanoparticles Containing a Vitamin B5‐Derived Ionizable Lipid for mRNA Vaccine DeliveryAdvanced Healthcare Materials, 2024
- A lipid nanoparticle platform incorporating trehalose glycolipid for exceptional mRNA vaccine safetyBioactive Materials, 2024
- Antigen/adjuvant‐free liposome induces adjuvant effects for enhancing cancer immunotherapyExploration, 2024
- Ionizable Lipid Nanoparticles for mRNA DeliveryAdvanced NanoBiomed Research, 2023
- The role of lipid components in lipid nanoparticles for vaccines and gene therapyAdvanced Drug Delivery Reviews, 2022